Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479668/805-30-25-5

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-8

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-7

Name:	us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
	Apr. 17, 2023	Dec. 31, 2022	Sep. 30, 2023
Summary Of Significant Accounting Policies [Line Items]
Purchase of treasury stock		$ 100.0
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration			$ 125.0
FlexBiosys, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration	$ 6.6		$ 42.0